Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Companies

bioFusion

bioFusion
Biofusion turn world class university research into business by investing in the world's most exciting science

The company in detail

Profile

Biofusion owns the rights to 100% of the university-owned research generated at two of the UK's leading universities – The University of Sheffield and Cardiff University. These exclusive partnerships enable us to invest in some the world's most advanced and exciting science, turning world class research into business through the creation of a growing portfolio of companies, in fields as varied as drug discovery, alternative energy and engineering.

Delivering for shareholders

We own the rights to an amazing depth and quality of research and we aim to turn that into real value for our shareholders. Our combination of short, medium and long term investments minimises risk and offers the potential for significant value growth for our shareholders.

As shareholders in Biofusion, our partner universities are rewarded and incentivised to ensure that their R&D spend is focused on generating world class IP and the academics are rewarded with shareholdings in the subsequent portfolio companies.

Partnering universities

In 2005, we signed an exclusive 10 year agreement with The University of Sheffield, the UK’s 5th ranked University for the quality of its life science IP, focusing on biosciences and commercialising all of their owned medical IP.

In 2007 we signed a second exclusive 10 year agreement with Cardiff University, the UK’s 5th ranked University for the overall quality of its IP, to commercialise all of their IP.

These partnerships allow everyone to play to their strengths – our partners focus on creation and innovation, and we take care of commercialisation. At the point of cross-over we are well integrated with each university’s existing technology transfer team, ensuring that progress is smooth and seamless.

Partnering strategy/interests

Biofusion are actively seeking licensees that are interested in acquiring the rights to selected technology opportunities available from Biofusion's university partners or from within Biofusion licensing itself.  All the technology opportunities listed on this site are available for licensing and we welcome contact from any organisations interested in discussing the technology further or wishing to develop the opportunities commercially.

Biofusion receives invention disclosures from its university partners and evaluates these disclosures for their commercial possibilities, and when possible licenses them to industry. If we successfully license a technology, the royalties are distributed between Biofusion, the university partner and the academic inventors of the technology.

We typically begin by reviewing an invention with its academic inventor to learn more about the technology, its state of development and what the potential applications or products might be. We then develop a commercial strategy, often considering the opinions of external consultants and industry sector experts.  After assessing the technology, we put in place a commercial plan to develop the technology and decide when to protect the intellectual property (if appropriate). We then actively seek feedback on the technology from relevant commercial organisations and use this information to help guide the commercial plan for the technology.  By doing this we hope to offer technologies that are relevent to real problems facing a wide range of sectors. 

The majority of Biofusion's portfolio opportunities are the subject of patent applications but we also offer opportunities that involve copyright (software), trademark licensing, and Material Transfer Agreements/Licences for biological material sales.

Out-licensing

Diagnostic, prognostic and therapeutic agents for ulcerative colitis, colon cancer and other cancers More
High speed protein identification More
Drug target More
Researchers at the University of Sheffield have developed and optimised new systems for the preparation of chiral amines in almost quantitative yield and as, essentially, one stereoisomer More
Novel prion disease therapeutics More
Modulators to promote cell proliferation More
Trb-2 modulators as therapeutics More
An electronic system to provide automated collection, delivery, analysis and feedback of a patient More
A novel colorimetric sensor with properties which include detecting the presence of DNA. More
A novel, fully-synthetic fluorcanasite material More

Services

Anti-Actin Hybridoma Cell Line More
Anti-cd15 Hybridoma More
Anti-cd63 Hybridoma More
Anti-CD63 Hybridoma More
IL-1RA KNOCKOUT mouse strain More
Partnering consultation free of charge
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us